Here is another experimental Phase 1 clinical trial that I find scientifically interesting - so I am keeping a close eye on - another second strategy to attempt to make MSS-CRC "cold" tumors "hot". This one is exclusively for MSS patients & exclusively at Johns Hopkins.
It uses two "epigenetic" drugs in combination with a PD-1 inhibitor. In CRC animal models the drugs remove immunosuppressive signals - so enhance the power of immunotherapies such as PD-1 inhibitors. At least in animal models...
There is no CRC human clinical trial data released yet.
https://clinicaltrials.gov/ct2/show/NCT ... 172&rank=1
Preclinical paper it is based on: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136565/
-DK